Side-by-side comparison of AI visibility scores, market position, and capabilities
US YC W23 AI credit underwriting automating financial statement spreading and credit memos at 80% faster processing for Slope/Pleo/Rho; $3.2M General Catalyst/YC seed competing with Ocrolus and Inscribe for B2B lending underwriting automation.
Accend is a United States-based AI-powered credit underwriting automation platform — backed by Y Combinator (W23) with $3.2 million in seed funding from YC, Adverb Ventures, General Catalyst, and 645 Ventures — providing B2B lending platforms, fintech lenders, and credit teams at companies like Slope, Pleo, Rho, and Evergrow with a human-in-the-loop AI credit analyst that automates financial statement spreading, credit analysis memo generation, and underwriting workflow management with 100% accuracy at 80% faster processing speeds and 10x faster credit memo production. Founded by a team with backgrounds from Brex, Deutsche Bank, and Credit Suisse, Accend applies the quantitative rigor of institutional credit analysis workflows to the automation challenge of scaling credit underwriting beyond the throughput of human analyst teams.
a2z Radiology AI raised $20M in 2025 for its whole-body AI that simultaneously screens for 24+ conditions across CT scans — from incidental cancers to cardiovascular risk — in a single automated read.
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disease, aortic aneurysm, bone density loss, and organ abnormalities. The AI acts as a second reader that radiologists can use to catch incidental findings that fall outside the primary reason for a scan — a major source of missed diagnoses.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.